Becton, Dickinson and Company $BDX Stock Purchased by Quadrant Capital Group LLC

Quadrant Capital Group LLC boosted its stake in Becton, Dickinson and Company (NYSE:BDX) by 34.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 11,015 shares of the medical instruments supplier’s stock after acquiring an additional 2,794 shares during the quarter. Quadrant Capital Group LLC’s holdings in Becton, Dickinson and Company were worth $1,972,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in Becton, Dickinson and Company during the second quarter valued at $3,721,533,000. Bank of America Corp DE purchased a new stake in shares of Becton, Dickinson and Company during the second quarter worth about $474,993,000. First Eagle Investment Management LLC increased its stake in shares of Becton, Dickinson and Company by 15.8% during the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock worth $2,090,675,000 after purchasing an additional 1,887,224 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Becton, Dickinson and Company during the second quarter worth about $247,372,000. Finally, Deutsche Bank AG acquired a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth about $204,226,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of the firm’s stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 6,906 shares of company stock worth $1,265,855 in the last quarter. Company insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Price Performance

NYSE:BDX opened at $200.21 on Friday. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $200.47. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock has a market cap of $55.16 billion, a PE ratio of 60.30, a P/E/G ratio of 13.10 and a beta of 0.21. The stock has a 50 day moving average price of $185.10 and a 200 day moving average price of $164.86.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The firm had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The firm’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.1%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Wolfe Research initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday. They set an “outperform” rating for the company. Bank of America lifted their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a “neutral” rating in a report on Monday, August 31st. Weiss Ratings upgraded Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. UBS Group began coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They set a “buy” rating and a $190.00 target price for the company. Finally, Citigroup reissued a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $185.07.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.